Continued Evaluation of Safety, Tolerability, and Clinical Outcomes in Participants with Parkinson’s Disease Throughout Three Years After Bemdaneprocel Administration (S26.003)

Key Points

• This study aims to evaluate the safety and clinical outcomes of bemdaneprocel in individuals with Parkinson's disease over a three-year period.
• Participants received bemdaneprocel and were monitored for three years.
• Safety and clinical outcomes were assessed throughout the duration of the study.
• Bemdaneprocel demonstrated a favorable safety profile over three years.
• Clinical outcomes showed improvements or stability in key metrics related to Parkinson's disease.